144 related articles for article (PubMed ID: 19838030)
1. [Revision of the informed consent form for patients based on investigation of adverse events of mFOLFOX6 regimen].
Kato T; Matsunaga Y; Motokawa S; Nakagaki S; Nagata N; Yoshida T; Muramatsu T; Kimura H; Ohashi Y; Kudou Y; Shino M; Yamazaki K; Boku N
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1697-702. PubMed ID: 19838030
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
3. [Safety and efficacy analysis of FOLFOX4 regimen in elderly compared to younger colorectal cancer patients].
Kuboki Y; Ichimura T; Ogura M; Matsuda M; Suenaga M; Shinozaki E; Matsuzaka S; Chin K; Mizunuma N; Hatake K
Gan To Kagaku Ryoho; 2008 May; 35(5):781-5. PubMed ID: 18487913
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of modified FOLFOX6 regimen in aged patients with nonresectable colorectal cancer].
Ishiguro T; Ishibashi K; Okada N; Kuwabara K; Miyazaki T; Yokoyama M; Matsuki M; Sano M; Inoue N; Ishida H
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2286-8. PubMed ID: 19106598
[TBL] [Abstract][Full Text] [Related]
5. [Drug information brochure for patients undergoing FOLFOX 4 chemotherapy based on survey of adverse reactions].
Imada H; Kawakami K; Hiraoka T; Higuchi S; Takahashi G; Aoyama T; Shinozaki E; Suenaga M; Matsuzaka S; Hama T
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1425-30. PubMed ID: 17876140
[TBL] [Abstract][Full Text] [Related]
6. [Effect of withdrawal of 5-fluorouracil bolus administration on recovery from neutropenia in colorectal cancer patients treated with mFOLFOX6 chemotherapy-comparison with total dosage reduction].
Ueda H; Demizu M; Oosawa M; Chihara S; Nakanishi Y; Maeda C; Yano K; Kimura F; Iwakawa S
Gan To Kagaku Ryoho; 2009 May; 36(5):789-93. PubMed ID: 19461179
[TBL] [Abstract][Full Text] [Related]
7. [Preparation of a brochure for patients undergoing FOLFIRI chemotherapy based on survey of adverse reactions].
Kamisugi K; Matsusaka S; Imada H; Shoji D; Nakamoto E; Yokokawa T; Kawakami K; Hirata Y; Nawano K; Ogawa M; Shinozaki E; Suenaga M; Mizunuma N; Hatake K; Hama T
Gan To Kagaku Ryoho; 2008 Aug; 35(8):1331-5. PubMed ID: 18701844
[TBL] [Abstract][Full Text] [Related]
8. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer.
Argyriou AA; Polychronopoulos P; Iconomou G; Koutras A; Makatsoris T; Gerolymos MK; Gourzis P; Assimakopoulos K; Kalofonos HP; Chroni E
Acta Oncol; 2007; 46(8):1131-7. PubMed ID: 17851880
[TBL] [Abstract][Full Text] [Related]
9. [PSK decreased FOLFOX4-induced peripheral neuropathy and bone marrow suppression in patients with metastatic colorectal cancer].
Shibata M; Shimura T; Nishina Y; Gonda K; Matsuo S; Abe H; Yajima Y; Nakamura I; Ohki S; Takenoshita S
Gan To Kagaku Ryoho; 2011 May; 38(5):797-801. PubMed ID: 21566440
[TBL] [Abstract][Full Text] [Related]
10. [Feasibility of peripheral vein during FOLFOX/FOLFIRI chemotherapy through peripheral venous system].
Kimura T; Iwase K; Aono T; Nakai S; Fujii M; Nishikawa K; Matsuda C; Shimada K; Hirota M; Nasu S; Wada D; Hasegawa J; Tanaka Y
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1889-94. PubMed ID: 19011337
[TBL] [Abstract][Full Text] [Related]
11. Interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX).
Jung KH; Kil SY; Choi IK; Seo JH; Shin C; Kim YS; Kim JH
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1181-2. PubMed ID: 17044215
[No Abstract] [Full Text] [Related]
12. [Modified FOLFOX6(mFOLFOX6)in metastatic colorectal carcinoma patients with poor performance status].
Nishi T; Hamamoto Y; Uemoto J; Onodera K; Warita E; Yamanaka Y
Gan To Kagaku Ryoho; 2012 Dec; 39(13):2557-60. PubMed ID: 23235179
[TBL] [Abstract][Full Text] [Related]
13. Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: a retrospective study of 69 male patients receiving modified FOLFOX6 therapy.
Tatsushima Y; Egashira N; Narishige Y; Fukui S; Kawashiri T; Yamauchi Y; Oishi R
Biomed Pharmacother; 2013 Feb; 67(1):39-42. PubMed ID: 23206755
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603.
Kanemitsu Y; Kato T; Shimizu Y; Inaba Y; Shimada Y; Nakamura K; Sato A; Moriya Y;
Jpn J Clin Oncol; 2009 Jun; 39(6):406-9. PubMed ID: 19389795
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin-induced immune mediated thrombocytopenia.
Beg MS; Komrokji RS; Ahmed K; Safa MM
Cancer Chemother Pharmacol; 2008 Oct; 62(5):925-7. PubMed ID: 18204841
[TBL] [Abstract][Full Text] [Related]
16. Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer.
Satoh T; Yamaguchi K; Boku N; Okamoto W; Shimamura T; Yamazaki K; Shi X; Mishima H
Invest New Drugs; 2012 Aug; 30(4):1511-8. PubMed ID: 21611734
[TBL] [Abstract][Full Text] [Related]
17. [A retrospective analysis of adverse events based on a dose and a schedule in patients who underwent paclitaxel- containing chemotherapy].
Yoshimura T; Hirade K; Iihara H; Ishihara M; Komori Y; Okayasu S; Matsuura K; Yasuda T; Itoh Y
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1721-6. PubMed ID: 18931576
[TBL] [Abstract][Full Text] [Related]
18. Multicenter phase II study of FOLFOX for metastatic colorectal cancer (mCRC) in Japan; SWIFT-1 and 2 study.
Nagata N; Kondo K; Kato T; Shibata Y; Okuyama Y; Ikenaga M; Tanemura H; Oba K; Nakao A; Sakamoto J; Mishima H
Hepatogastroenterology; 2009; 56(94-95):1346-53. PubMed ID: 19950789
[TBL] [Abstract][Full Text] [Related]
19. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
[TBL] [Abstract][Full Text] [Related]
20. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.
Polyzos A; Tsavaris N; Gogas H; Souglakos J; Vambakas L; Vardakas N; Polyzos K; Tsigris C; Mantas D; Papachristodoulou A; Nikiteas N; Karavokyros JG; Felekouras E; Griniatsos J; Giannopoulos A; Kouraklis G
Oncology; 2009; 76(1):36-41. PubMed ID: 19033714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
